sarilumab high dose (400mg) - for COVID-19 method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

clinical improvement 2.09 [1.00, 4.36]> 10%1 study (1 / -)97.5 %highnot evaluable lowcrucial-
deaths 0.78 [0.34, 1.80]< 10%1 study (1 / -)71.7 %highnot evaluable lowcrucial-
death or ventilation 0.39 [0.18, 0.82]< 10%1 study (1 / -)99.4 %highnot evaluable lowimportant-
ventilation 0.27 [0.10, 0.71]< 10%1 study (1 / -)99.6 %highnot evaluable lowimportant-
off oxygenation 1.99 [0.95, 4.15]> 10%1 study (1 / -)96.7 %highnot evaluable lownon important-

LoD: level of demonstration ( demonstrated, suggested, inconclusive, safety concerns);
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



This meta-analysis covered 1 pathologies: 87,95,94,90,91,97 91